Patents by Inventor Wolfgang Wurst
Wolfgang Wurst has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240124891Abstract: The present invention relates to CRISPR-mediated means and methods, e.g., for adjustably induction of multiple gene expression and subsequent cell reprogramming. Particularly, the CRISPR-mediated means and methods of the present invention relate to conversion of endogenous glial cells into GABAergic neurons representing an effective method for cell reprogramming.Type: ApplicationFiled: February 17, 2022Publication date: April 18, 2024Inventors: Wolfgang WURST, Florian GIESERT, Jessica GIEHRL-SCHWAB, Benedict RAUSER
-
Publication number: 20240041990Abstract: The present invention relates to composition comprising a clustered, regularly interspaced, short palindromic repeats (CRISPR) system comprising i) at least one CRISPR-associated protein 13 (Cas13) or a nucleotide sequence encoding said Cas13 protein fused with at least one nuclear localization signal (NLS) fused to at least one nuclear export sequence (NES) and ii) at least one guide RNA (gRNA) or a nucleotide sequence encoding said gRNA capable of hybridizing with one or more target RNA molecules.Type: ApplicationFiled: December 21, 2021Publication date: February 8, 2024Inventors: Christoph GRUBER, Dong-Jiunn Jeffery TRUONG, Florian GIESERT, Wolfgang WURST
-
Publication number: 20230024301Abstract: The present invention relates a vector system and a vector system for use in a method of treating a disease, each comprising a first vector and a second vector. The present invention further relates to the first vector, the second vector and a combination of the first vector and the second vector. In addition, the present invention relates to a pharmaceutical composition comprising the vector system of the invention or the combination of the invention.Type: ApplicationFiled: October 2, 2020Publication date: January 26, 2023Inventors: Christian Kupatt, Wolfgang Wurst, Dong-Jiunn Jeffery Truong
-
Publication number: 20210388364Abstract: The invention provides a method for detecting a specific splice event of a gene of interest, wherein the specific splice event creates a specific splice product, which comprises an exon of interest, wherein the method comprises: (i) Inserting a split intein—heterologous polynucleotide construct into the exon of interest, wherein the split intein comprises an N-terminal splicing region upstream of the heterologous polynucleotide and a C-terminal splicing region downstream of the heterologous polynucleotide; and (ii) detecting the heterologous polynucleotide and/or the expression product of the heterologous polynucleotide. The present invention also provides the use of the split intein—heterologous polynucleotide construct, the nucleic acid encoding this construct, the vector and the host cell comprising the nucleic acid as well as a kit for detecting a specific splice event of a gene of interest.Type: ApplicationFiled: February 6, 2020Publication date: December 16, 2021Inventors: Gil Gregor Westmeyer, Dong-Jiunn Jeffery, Wolfgang Wurst
-
Patent number: 10214723Abstract: The present invention relates to a method of producing a non-human, mammalian oocyte carrying a modified target sequence in its genome, the method comprising the steps of introducing into a non-human, mammalian oocyte: (a) a clustered, regularly interspaced, short palindromic repeats (CRISPR)-associated protein 9 (Cas9 protein) or a nucleic acid molecule encoding said Cas9 protein; and (b-i) a target sequence specific CRISPR RNA (crRNA) and a trans-activating crRNA (tracr RNA) or a nucleic acid molecule encoding said RNAs; or (b-ii) a chimaeric RNA sequence comprising a target sequence specific crRNA and tracrRNA or a nucleic acid molecule encoding said RNA; wherein the Cas9 protein introduced in (a) and the RNA sequence(s) introduced in (b-i) or (b-ii) form a protein/RNA complex that specifically binds to the target sequence and introduces a single or double strand break within the target sequence.Type: GrantFiled: July 13, 2016Date of Patent: February 26, 2019Assignee: HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELTInventors: Ralf Kühn, Wolfgang Wurst, Oskar Ortiz Sanchez
-
Patent number: 9783780Abstract: The present invention relates to a method of producing a non-human, mammalian oocyte carrying a modified target sequence in its genome, the method comprising the steps of introducing into a non-human, mammalian oocyte: (a) a clustered, regularly interspaced, short palindromic repeats (CRISPR)-associated protein 9 (Cas9 protein) or a nucleic acid molecule encoding said Cas9 protein; and (b-i) a target sequence specific CRISPR RNA (crRNA) and a trans-activating crRNA (tracr RNA) or a nucleic acid molecule encoding said RNAs; or (b-ii) a chimaeric RNA sequence comprising a target sequence specific crRNA and tracrRNA or a nucleic acid molecule encoding said RNA; wherein the Cas9 protein introduced in (a) and the RNA sequence(s) introduced in (b-i) or (b-ii) form a protein/RNA complex that specifically binds to the target sequence and introduces a single or double strand break within the target sequence.Type: GrantFiled: August 26, 2015Date of Patent: October 10, 2017Assignee: HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELTInventors: Ralf Kühn, Wolfgang Wurst, Oskar Ortiz Sanchez
-
Publication number: 20160319242Abstract: The present invention relates to a method of producing a non-human, mammalian oocyte carrying a modified target sequence in its genome, the method comprising the steps of introducing into a non-human, mammalian oocyte: (a) a clustered, regularly interspaced, short palindromic repeats (CRISPR)-associated protein 9 (Cas9 protein) or a nucleic acid molecule encoding said Cas9 protein; and (b-i) a target sequence specific CRISPR RNA (crRNA) and a trans-activating crRNA (tracr RNA) or a nucleic acid molecule encoding said RNAs; or (b-ii) a chimaeric RNA sequence comprising a target sequence specific crRNA and tracrRNA or a nucleic acid molecule encoding said RNA; wherein the Cas9 protein introduced in (a) and the RNA sequence(s) introduced in (b-i) or (b-ii) form a protein/RNA complex that specifically binds to the target sequence and introduces a single or double strand break within the target sequence.Type: ApplicationFiled: July 13, 2016Publication date: November 3, 2016Inventors: Ralf KÜHN, Wolfgang WURST, Oskar ORTIZ SANCHEZ
-
Publication number: 20150376652Abstract: The present invention relates to a method of producing a non-human, mammalian oocyte carrying a modified target sequence in its genome, the method comprising the steps of introducing into a non-human, mammalian oocyte: (a) a clustered, regularly interspaced, short palindromic repeats (CRISPR)-associated protein 9 (Cas9 protein) or a nucleic acid molecule encoding said Cas9 protein; and (b-i) a target sequence specific CRISPR RNA (crRNA) and a trans-activating crRNA (tracr RNA) or a nucleic acid molecule encoding said RNAs; or (b-ii) a chimaeric RNA sequence comprising a target sequence specific crRNA and tracrRNA or a nucleic acid molecule encoding said RNA; wherein the Cas9 protein introduced in (a) and the RNA sequence(s) introduced in (b-i) or (b-ii) form a protein/RNA complex that specifically binds to the target sequence and introduces a single or double strand break within the target sequence.Type: ApplicationFiled: August 26, 2015Publication date: December 31, 2015Inventors: Ralf KÜHN, Wolfgang WURST, Oskar ORTIZ SANCHEZ
-
Patent number: 9085767Abstract: The present invention relates to a novel class of gene trap vector (enhanced gene trap vectors, eGTV) for efficiently identifying silent or weakly expressed target genes in mammalian genomes, methods of their production and methods for identifying and mutating target genes by using the enhanced gene trap vectors. The gene trap vectors of the present invention can also be used for inducing the expression of silent genes and enhancing the expression of weakly expressed genes. The use of the enhanced gene trap vectors for creating transgenic organisms to identify gene function and to validate pharmaceutical compounds prior to clinical applications is a further aspect of the present invention.Type: GrantFiled: November 28, 2005Date of Patent: July 21, 2015Assignees: FRANKGEN BIOTECHNOLOGIE AG, GSF FORSCHUNGSZENTRUM FUR UMWELT UND GESUNDHEIT GMBH, MPG MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V.Inventors: Harald Von Melchner, Frank Schnütgen, Wolfgang Wurst, Patricia Ruiz
-
Publication number: 20140304847Abstract: The present invention relates to a method for modifying a target sequence in the genome of a mammalian cell, the method comprising the step of introducing into a mammalian cell: a. one or more compounds that introduce double-strand breaks in said target sequence; b. one or more DNA molecules comprising a donor DNA sequence to be incorporated by homologous recombination into the genomic DNA of said mammalian cell within said target sequence, wherein said donor DNA sequence is flanked upstream by a first flanking element and downstream by a second flanking element, wherein said first and second flanking element are different and wherein each of said first and second flanking sequence are homologous to a continuous DNA sequence on either side of the double-strand break introduced by said one or more compounds of a. within said target sequence in the genome of said mammalian cell; and c.Type: ApplicationFiled: June 6, 2012Publication date: October 9, 2014Inventors: Ralf Kühn, Wolfgang Wurst
-
Patent number: 8530168Abstract: The present invention relates to a fusion protein comprising a Caspase domain or a functionally active variant thereof and a ligand binding domain of a nuclear hormone receptor, a nucleic acid coding for the fusion protein, a vector or cell comprising the nucleic acid, a method of producing the fusion protein, a non-human transgenic animal containing the nucleic acid, the use of the fusion protein for ligand-mediated induction of apoptosis of a cell, or for studying the function of a cell, tissue and/or organ or the use of a transgenic organism for studying the function of a cell at various developmental stages or as a disease model, a method for inducing apoptosis of a cell expressing a fusion protein or for identifying a ligand, or a medicament comprising a fusion protein, the nucleic acid, the vector or the cell, particularly for the treatment of cancer or for or after transplantation, particularly as safety mechanism.Type: GrantFiled: June 20, 2008Date of Patent: September 10, 2013Assignee: Helmholtz Zentrum Munich Deutsches Forschungszentrum fuer Gesundheit und Umwelt (GmbH)Inventors: Yuanyuan Chu, Ralf Kuehn, Wolfgang Wurst
-
Publication number: 20130212725Abstract: The present invention relates to a method of modifying a target sequence in the genome of a eukaryotic cell, the method comprising the step: (a) introducing into the cell a fusion protein comprising a DNA-binding domain of a Tal effector protein and a non-specific cleavage domain of a restriction nuclease or a nucleic acid molecule encoding the fusion protein in expressible form, wherein the fusion protein specifically binds within the target sequence and introduces a double strand break within the target sequence. The present invention further relates to the method of the invention, wherein the modification of the target sequence is by homologous recombination with a donor nucleic acid sequence further comprising the step: (b) introducing a nucleic acid molecule into the cell, wherein the nucleic acid molecule comprises the donor nucleic acid sequence and regions homologous to the target sequence.Type: ApplicationFiled: June 7, 2011Publication date: August 15, 2013Applicant: HELMHOLTZ ZENTRUM MUNCHEN DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UNDInventors: Ralf Kühn, Wolfgang Wurst, Melanie Meyer
-
Publication number: 20120276537Abstract: The present invention relates to a method of modifying a target sequence in the genome of a mammalian or avian oocyte by homologous recombination with a donor nucleic acid sequence, the method comprising the steps (a) introducing into the oocyte a zinc finger nuclease or a nucleic acid molecule encoding the zinc finger nuclease in expressible form, wherein the zinc finger nuclease specifically binds within the target sequence and introduces a double strand break within the target sequence; and (b) introducing a nucleic acid molecule into the oocyte, wherein the nucleic acid molecule comprises the donor nucleic acid sequence and regions homologous to the target sequence. The present invention further relates to a method of producing a non-human mammal or an avian carrying a modified target sequence in its genome.Type: ApplicationFiled: October 28, 2010Publication date: November 1, 2012Inventors: Ralf Kühn, Wolfgang Wurst, Melanie Meyer
-
Publication number: 20110061118Abstract: The present invention relates to a DNA molecule comprising: (a) a first DNA sequence comprising: (aa) a coding sequence giving rise upon transcription to a factor that contributes to the reprogramming of a somatic cell into an induced pluripotent stem (iPS) cell; (ab) a promoter mediating the transcription of said coding sequence; and (ac) two sequence motifs that mediate excision of (aa) and/or (ab) from the DNA molecule, wherein one sequence motif is positioned 5? and the other sequence motif is positioned 3? of the sequence to be excised; (b) a second DNA sequence comprising a sequence motif that mediates site-specific integration of (a) into another DNA molecule.Type: ApplicationFiled: March 17, 2009Publication date: March 10, 2011Applicant: Helmholtz Zentrum MunchenInventors: Ralf Kühn, Wolfgang Wurst
-
Publication number: 20110023137Abstract: The present invention relates to a fusion protein comprising a Caspase domain or a functionally active variant thereof and a ligand binding domain of a nuclear hormone receptor, a nucleic acid coding for the fusion protein, a vector or cell comprising the nucleic acid, a method of producing the fusion protein, a non-human transgenic animal containing the nucleic acid, the use of the fusion protein for ligand-mediated induction of apoptosis of a cell, or for studying the function of a cell, tissue and/or organ or the use of a transgenic organism for studying the function of a cell at various developmental stages or as a disease model, a method for inducing apoptosis of a cell expressing a fusion protein or for identifying a ligand, or a medicament comprising a fusion protein, the nucleic acid, the vector or the cell, particularly for the treatment of cancer or for or after transplantation, particularly as safety mechanism.Type: ApplicationFiled: June 20, 2008Publication date: January 27, 2011Applicant: HELMHOLLZ ZENLRUM MUNICH DEULSCHES FORSCHUNG FUER GESUNDHEIT AND UNWELTInventors: Yuanyuan Chu, Ralf Kuehn, Wolfgang Wurst
-
Publication number: 20100299771Abstract: The present invention relates to a combination of DNA segments comprising: (a) a first segment comprising in 5? to 3? or 3? to 5? order: (aa) a promoter; (ab) a first DNA sequence comprising: (i) a DNA sequence giving rise upon transcription to the sense strand of an shRNA molecule; (ii) a transcriptional stop element which is flanked by a first type of recombinase recognition sequences; and (iii) a DNA sequence giving rise upon transcription to the antisense strand of an shRNA molecule; (b) a second segment comprising in 5? to 3? or 3? to 5? order: (ba) a promoter; (bb) a second DNA sequence comprising: (i) a DNA sequence giving rise upon transcription to the sense strand of an shRNA molecule; (ii) a transcriptional stop element which is flanked by a second type of recombinase recognition sequences; and (iii) a DNA sequence giving rise upon transcription to the antisense strand of an shRNA molecule; wherein (i) said first type of recombinase recognition sequences are recognized and recombined by a recombinasType: ApplicationFiled: September 17, 2008Publication date: November 25, 2010Applicant: HELMHOLTZ ZENTRUM MUNCHEN- DEUTSCHES FORSCHUNGZENTRUM FUR GESUNDHEIT UND UMWELT(GMBH)Inventors: Ralf Kühn, Wolfgang Wurst, Patricia Steuber-Buchberger
-
Publication number: 20100242127Abstract: The present invention relates to a method for identifying a compound capable of modulating an anxiety or depression disorder comprising the steps of: (a) contacting a composition comprising a B-Raf protein or a B-Raf gene in expressible form or a transcript thereof with a compound under conditions that allow for an interaction of the B-Raf protein or the B-Raf gene or a transcript thereof and the compound; and (b) measuring whether said interaction, if any, results in (i) a change of B-Raf kinase activity compared to B-Raf kinase activity in the absence of said compound; (ii) a modulation of the expression of the B-Raf gene compared to B-Raf gene expression in the absence of said compound; or (iii) the formation of a complex between the compound and the B-Raf protein, wherein such a change in activity, modulation of expression or the formation of a complex is indicative of the compound being a modulator of an anxiety or depression disorder.Type: ApplicationFiled: June 3, 2008Publication date: September 23, 2010Applicant: HELMHOLTZ ZENTRUM MUNCHENInventors: Christiane Hitz, Sabine Hölter, Ralf Kühn, Wolfgang Wurst, Benedikt Wefers
-
Publication number: 20100199360Abstract: The present invention relates to a novel class of gene trap vector (enhanced gene trap vectors, eGTV) for efficiently identifying silent or weakly expressed target genes in mammalian genomes, methods of their production and methods for identifying and mutating target genes by using the enhanced gene trap vectors. The gene trap vectors of the present invention can also be used for inducing the expression of silent genes and enhancing the expression of weakly expressed genes. The use of the enhanced gene trap vectors for creating transgenic organisms to identify gene function and to validate pharmaceutical compounds prior to clinical applications is a further aspect of the present invention.Type: ApplicationFiled: November 28, 2005Publication date: August 5, 2010Applicants: FRANKGEN BIOTECHNOLOGIE AG., GSF FORSCHUNGSZENTRUM FUR UMWELT UND GESUNDHEIT GMBH, MPG MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.Inventors: Harald Von Melchner, Frank Schnutgen, Wolfgang Wurst, Patricia Ruiz
-
Publication number: 20090113561Abstract: A new type of gene trap cassette, which can induce conditional mutations, relies on directional site-specific recombination systems, which can repair and re-induce gene trap mutations when activated in succession. After the gene trap cassettes are inserted into the genome of the target organism, mutations can be activated at a particular time and place in somatic cells. The gene trap cassettes also create multipurpose alleles amendable to a wide range of post-insertional modifications. Such gene trap cassettes can be used to mutationally inactivate all cellular genes temporally and/or spatially. Cells which contain the inventive gene trap cassette can be used for identification and/or isolation of genes and for the creation of transgenic organisms to study gene function at various developmental stages, including the adult, as well as for the creation of animal models of human disease useful for in vivo drug target validation.Type: ApplicationFiled: November 28, 2005Publication date: April 30, 2009Applicant: FRANKGEN BIOTECHNOLOGIE AGInventors: Harald Von Melchner, Frank Schnutgen, Wolfgang Wurst, Particia Ruiz, Silke De-Zolt, Thomas Floss, Jens Hansen
-
Publication number: 20040133933Abstract: This invention relates to a novel DNA sequence encoding a bHLH transcription factor in vertebrates, preferably mammals, e.g. in mice or humans, as well as the expressed transcription factor. The invention further relates to vectors containing said DNA sequences and host cells transformed by these vectors. Furthermore, the invention encompasses antibodies specific for the transcription factors as well as the use of the DNA sequences and transcription factors in the diagnosis or therapy of neurodegenerative diseases, e.g. Parkinson's disease. The present invention further relates to an ex vivo method of producing dopaminergic cells and the therapeutic use of these dopaminergic cells.Type: ApplicationFiled: July 31, 2003Publication date: July 8, 2004Inventors: Jordi Guimera-Vilaro, Wolfgang Wurst, Daniela Vogt-Weisenhorn, Laure Bally-Cuif